Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

VTV Therapeutics Inc (VTVT) USD0.01 A

Sell:$1.73 Buy:$1.80 Change: No change
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$1.73
Buy:$1.80
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$1.73
Buy:$1.80
Change: No change
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Contact details

Address:
3980 Premier Dr, Suite 310
HIGH POINT
27265
United States
Telephone:
+1 (336) 8410300
Website:
vtvtherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VTVT
ISIN:
US9183851057
Market cap:
$145.75 million
Shares in issue:
83.29 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Robin Abrams
    Executive Chairman of the Board
  • Stephen Holcombe
    President, Chief Executive Officer
  • Rudy Howard
    Chief Financial Officer, Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.